中宠股份(002891) - 2022 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2022 was ¥792,893,440.85, representing a 41.58% increase compared to ¥560,025,402.84 in the same period last year[6]. - Net profit attributable to shareholders was ¥23,397,267.22, up 10.73% from ¥21,129,830.61 year-on-year[6]. - The total operating revenue for the current period reached ¥792,893,440.85, a significant increase of 41.4% compared to ¥560,025,402.84 in the previous period[26]. - The net profit attributable to the parent company was ¥23,397,267.22, representing an increase of 10.7% from ¥21,129,830.61 in the previous period[28]. - The company reported a comprehensive income total of ¥29,702,794.91, compared to ¥27,463,410.90 in the prior period, reflecting a growth of 8.1%[30]. Cash Flow and Financial Activities - The net cash flow from operating activities was -¥62,788,556.39, a decrease of 204.69% compared to -¥20,607,568.48 in the previous year[6]. - Cash flow from operating activities was ¥751,754,705.13, an increase from ¥523,425,021.64 in the previous period, indicating a growth of 43.6%[31]. - The net cash flow from operating activities was -62,788,556.39 CNY, compared to -20,607,568.48 CNY in the previous period, indicating a decline in operational cash generation[33]. - Total cash outflow from investing activities was 105,293,295.94 CNY, down from 237,103,134.63 CNY, reflecting reduced investment expenditures[33]. - The net cash flow from financing activities improved to 38,367,532.69 CNY, compared to -58,673,733.06 CNY in the previous period, showing a positive shift in financing operations[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,096,606,202.33, a 2.70% increase from ¥3,015,181,615.47 at the end of the previous year[6]. - The total liabilities rose to ¥1,122,914,903.19, compared to ¥1,069,380,292.64 in the previous period, marking an increase of 5.0%[30]. - The company's total current liabilities were approximately ¥869.83 million, slightly up from ¥868.48 million, showing a marginal increase of about 0.15%[22]. - Long-term borrowings increased to approximately ¥149.64 million from ¥113.72 million, reflecting a growth of about 31.6%[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,000, with the largest shareholder holding 26.41% of the shares[13]. - The company reported a total of 77,685,750 shares held by Yantai Zhongxing Biotechnology Co., Ltd., making it the largest shareholder[18]. - The top ten shareholders collectively hold a significant portion of the company, with the largest shareholder owning approximately 24.5% of the total shares[18]. Operating Costs and Expenses - The company reported a 47.79% increase in operating costs, amounting to ¥64,653,120.00, compared to ¥43,746,500.00 in the previous year[9]. - The total operating costs amounted to ¥748,642,638.23, up 43.9% from ¥519,876,118.72 in the prior period[26]. - The company experienced a 119.41% rise in financial expenses, totaling ¥627,660.00, compared to ¥286,070.00 in the previous year[9]. - Research and development expenses increased to ¥11,768,512.49, up 23.8% from ¥9,503,858.98 in the previous period[28]. Cash and Equivalents - The company's cash and cash equivalents decreased to approximately ¥325.57 million from ¥350.86 million, a decline of about 7.2%[20]. - Cash and cash equivalents at the end of the period stood at 313,310,788.36 CNY, slightly up from 299,030,321.43 CNY[33]. Inventory and Receivables - Accounts receivable increased significantly to approximately ¥441.99 million, up from ¥345.35 million, representing a growth of about 28%[20]. - Inventory levels rose to approximately ¥533.31 million, compared to ¥516.67 million at the beginning of the year, indicating an increase of about 3.2%[20]. Other Information - The company received government subsidies amounting to ¥657,429.19 during the reporting period[8]. - The company is actively exploring new product development and market expansion strategies to enhance its competitive position in the industry[19]. - The company did not conduct an audit for the first quarter report, which may affect the reliability of the financial data presented[34].